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Abstract
Medicare beneficiaries do not have to pay for screening colonoscopies but must pay coinsurance if 
a polyp is removed via polypectomy. Likewise, beneficiaries do not have to pay for fecal occult 
blood tests but are liable for cost-sharing for diagnostic colonoscopies after a positive test. 
Legislative and regulatory requirements related to colorectal cancer screening are described, and 
on the basis of Medicare claims, it is estimated that Medicare spending would increase by $48 
million annually if Medicare were to waive cost-sharing requirements for these services. The 
economic impact on Medicare if beneficiaries were not responsible for any cost-sharing 
requirements related to colorectal cancer screening services is described.
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INTRODUCTION
Colorectal cancer (CRC) screening identifies premalignant polyps that can be removed and 
early-stage tumors that can be treated effectively. Early detection is cost-effective or even 
cost-saving in comparison with no screening.1 Despite screening recommendations and clear 
evidence for the benefits of CRC screening, many adults are not up to date with screening.2 
The US Preventive Services Task Force (USPSTF) strongly recommends screening for CRC 
beginning at the age of 50 years and continuing until the age of 75 years.3 Because of the 
important role of screening in reducing the incidence of CRC and mortality, increasing the 
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proportion of US adults aged 50 to 75 years who are screened for CRC in accordance with 
USPSTF recommendations is a leading national health indicator in Healthy People 2020.
When Medicare covers a preventive service rated as A or B by the USPSTF, the Affordable 
Care Act requires coverage without cost-sharing. Nongrandfathered private health plans 
must cover all USPSTF-recommended A and B services without cost-sharing. Consistent 
with the Affordable Care Act, Medicare beneficiaries do not have to pay the part B 
deductible or coinsurance when they have a screening colonoscopy or fecal occult blood test 
(FOBT). However, they may face unexpected out-of-pocket liabilities when a polyp is 
detected and removed during a screening colonoscopy. In that case, the service is considered 
to be a diagnostic procedure (colonoscopy with polypectomy) rather than a screening 
colonoscopy, and patients are billed a copay. Beneficiaries also are responsible for the part 
B deductible and coinsurance when a colonoscopy is performed as part of a 2-step screening 
process after a positive FOBT. Waiving the Medicare cost-sharing requirements under these 
2 clinical scenarios could increase the use of CRC screening but could also increase costs to 
the Medicare program.
Colonoscopies performed with polypectomies can fall into a clinical gray zone in terms of 
whether they are categorized as preventive or therapeutic services. The USPSTF CRC 
screening recommendation states that “screening for colorectal cancer reduces mortality 
through detection and treatment of early-stage cancer and detection and removal of 
adenomatous polyps,” and it notes that polyp removal is a key component of CRC screening 
that makes it an effective clinical preventive service. In February 2013, the federal 
government issued frequently asked questions about the Affordable Care Act, which state 
that nongrandfathered group health plans are required to cover polypectomy without cost-
sharing because “polyp removal is an integral part of a colonoscopy.”4 However, Medicare 
regulations currently require Medicare beneficiaries to pay coinsurance, but not a deductible, 
for colonoscopies performed with polypectomies. In 2013, representatives introduced 
legislation that would eliminate the coinsurance for polypectomies under Medicare.5
Efforts to reduce cost-sharing for CRC screening and detection have focused almost 
exclusively on patients initially screened with colonoscopy. None of the aforementioned 
policy changes affect cost-sharing for patients initially screened via FOBT. Physicians may 
be reluctant to recommend FOBT to their patients if payers eliminate cost-sharing for 
patients screened via colonoscopy but continue to require cost-sharing for colonoscopies 
performed after a positive FOBT.6
COST TO MEDICARE OF ELIMINATING THE COST-SHARING 
REQUIREMENTS
It is important to examine how waiving cost-sharing for colonoscopies performed with a 
polypectomy and colonoscopies after a positive FOBT would affect Medicare spending. 
Using data from the 2006-2010 Medicare Current Beneficiary Survey and linked claims, we 
estimated the number of colonoscopies currently subject to patient cost-sharing in Medicare 
among patients aged 65 to 75 years. The Medicare Current Beneficiary Survey is a random 
survey of Medicare beneficiaries and includes Medicare claims for respondents enrolled in 
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fee-for-service Medicare. We used linked claims from the beneficiaries’ data to identify tests 
and procedures, Medicare reimbursements, and beneficiaries’ out-of-pocket payments. The 
latter include payments by supplemental payers. Because our goal was to estimate total costs 
to the Medicare program, we did not limit the sample to beneficiaries with full-year part B 
enrollment. Likewise, we included colonoscopies regardless of whether they (or the FOBT 
that preceded them) occurred on or off the USPSTF-recommended time schedule, and we 
did not determine the appropriateness of a colonoscopy (or FOBT) on the basis of the time 
since a patient’s previous screen.
Because claims data do not directly identify colonoscopies performed for purposes of 
screening versus diagnostic follow-up of symptoms, we restricted our attention to 
colonoscopies performed in beneficiaries without gastrointestinal symptoms or other 
conditions for which a diagnostic colonoscopy would be appropriate7 (see the online 
supporting information for a list of relevant procedure codes and other methodological 
details). We stratified colonoscopies by whether they were preceded by an FOBT in the 
previous 90 days. Colonoscopies performed within 90 days of an FOBT were considered 
FOBT follow-up colonoscopies, whereas all others were considered initial colonoscopies.
We projected costs to 2014 on the basis of projected growth in the population aged 65 to 75 
years and the historical rate of growth in the Medicare Economic Index.8 We further inflated 
costs to account for Medicare reimbursements for anesthesiologist involvement in screening 
colonoscopies, which is increasing.9
We estimate that in 2014, Medicare will pay for 575,000 initial screening colonoscopies, of 
which 209,000 will be performed with a polypectomy (Table 1). Under current payment 
policies, Medicare will pay $166 million for initial colonoscopies performed with a 
polypectomy, and the total coinsurance will be $42 million (20% of total payments).
We estimate that Medicare will pay for 33,000 colonoscopies (with and without 
polypectomies) after an FOBT in 2014. Medicare will spend $24 million for these 
procedures, whereas the total coinsurance for these procedures will be $6 million. In total, 
we estimate that Medicare spending would increase by $48 million ($42 million plus $6 
million) annually if Medicare eliminated cost-sharing for initial screening colonoscopies 
performed with a polypectomy and colonoscopies performed after a positive FOBT. 
Medicare spending on colonoscopies would increase by approximately 10%. These figures 
may overestimate costs to Medicare because we did not distinguish between polypectomies 
performed during a screening colonoscopy and polypectomies performed during a 
diagnostic colonoscopy, which, unless it occurred after a positive FOBT, would not be 
exempt from cost-sharing.
POTENTIAL BENEFIT OF ELIMINATING COST-SHARING REQUIREMENTS
One potential barrier to CRC screening is cost. Out-of-pocket costs may discourage the use 
of preventive care, including CRC screening. Research examining the impact of eliminating 
coinsurance for CRC screening found that waiving coinsurance for colonoscopy screening 
resulted in an 18% increase in colonoscopy screening.10 We do not know to what extent 
Medicare beneficiaries are aware of their potential out-of-pocket liabilities when they 
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consent to a colonoscopy. If many are unaware, then the impact of eliminating cost-sharing 
for polyp removal could be smaller.
However, it is clear that eliminating cost-sharing requirements could increase the number of 
initial screening colonoscopies and follow-up colonoscopies after a positive FOBT. Thus, 
policies to reduce cost-sharing have the potential to increase the number of individuals 
receiving CRC screening as recommended. Increasing screening is a desirable approach not 
only to reduce the incidence of CRC and mortality but also to control the costs of CRC 
treatment.11
DISCUSSION
CRC screening highlights the sometimes arbitrary distinctions between preventive, 
diagnostic, and even therapeutic services. Offering screening services without cost-sharing 
counteracts cognitive biases and promotes individuals’ initial contact with the health care 
system. Such an incentive is needed to help improve the uptake of CRC screening. If, 
because of these same cognitive biases, patients are reluctant to follow up on a positive 
screen, payers could consider reducing cost-sharing requirements for diagnostic tests or 
reclassify them as screening tests.
An important component of colonoscopies is to find and remove adenomatous polyps. 
Colonoscopies and subsequent polypectomies, the mechanism through which the mortality 
benefit from screening is derived, could be considered part of the screening process. 
Similarly, FOBT follow-up colonoscopies could also be considered a part of the screening 
process because they are required to achieve the mortality benefit. Because the mortality 
benefit for CRC can be achieved only if the entire process is completed, all of these steps 
could be considered a part of the screening process. Efforts addressing barriers to CRC 
screening such as cost-sharing requirements may be effective in increasing screening rates 
and reducing the health and economic burden of CRC.
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TABLE 1
Projected 2014 Volume and Spending on Colorectal Cancer Screening–Related Procedures in the Medicare 
Fee-for-Service Population (Aged 65-75 Years)
Spending
(Millions of 2014 US Dollars)
a
Total Procedures per Year (1000s)
a Medicare Reimbursements Coinsurance
Initial colonoscopies
 Colonoscopy without polypectomy 366 (321-411) 287 (247-328) 0 (0-0)
 Colonoscopy with polypectomy 209 (177-241) 166 (128-204) 42 (0-51)
 Total 575 (513-637) 453 (394-512) 42 (0-50)
FOBT follow-up colonoscopies
 Colonoscopy without polypectomy 20 (0-40) 15 (1-28) 4 (0-10)
 Colonoscopy with polypectomy 13 (9-18) 10 (8-12) 2 (0-3)
 Total 33 (14-52) 24 (11-37) 6 (0-10)
Colonoscopies performed within 90 days of undergoing an FOBT were considered follow-up colonoscopies, whereas all others were considered 
initial colonoscopies.
a
Ninety-five percent confidence interval are presented in parentheses.
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